Krystal Biotech (KRYS) Total Liabilities (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Total Liabilities data on file, last reported at $120.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 33.98% year-over-year to $120.2 million; the trailing twelve-month figure through Mar 2026 stood at $120.2 million (up 33.98% YoY), and the FY2025 full-year result was $114.2 million, up 4.36% from the prior year.
• Total Liabilities improved to $120.2 million in Q1 2026, from $114.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $120.2 million in Q1 2026 to a low of $30.9 million in Q2 2023.
• A 5-year average of $70.1 million and a median of $68.3 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 452.48% in 2022 and tumbled 38.11% in 2023, its largest moves.
• Tracing KRYS's Total Liabilities over 5 years: stood at $36.2 million in 2022, then rose by 9.65% to $39.7 million in 2023, then soared by 175.62% to $109.5 million in 2024, then increased by 4.36% to $114.2 million in 2025, then advanced by 5.26% to $120.2 million in 2026.
• Business Quant data shows KRYS's Total Liabilities at $120.2 million in Q1 2026, $114.2 million in Q4 2025, and $102.2 million in Q3 2025.